Abstract
Since the introduction of NOAC (non-vitamin K antagonist oral anticoagulants) in 2011 as thromboprophylactic treatment for patients with atrial fibrillation, AF, the number of patients with a diagnosis of atrial fibrillation has increased markedly in our health care registers. The proportion of patients treated with warfarin or NOAC has increased from 47 % to 58 % in 2013. The use of acetylsalicylic acid in patients is decreasing rapidly in patients with AF. NOAC are mostly prescribed by specialists and are mainly used in younger patients with lower CHA2DS2-VASc scores and lower risk for renal insufficiency and bleeding.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Anticoagulants / therapeutic use*
-
Antithrombins / therapeutic use
-
Aspirin / therapeutic use
-
Atrial Fibrillation* / drug therapy
-
Atrial Fibrillation* / prevention & control
-
Benzimidazoles / therapeutic use
-
Cohort Studies
-
Dabigatran
-
Drug Prescriptions / statistics & numerical data
-
Drug Utilization
-
Factor Xa Inhibitors / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Morpholines / therapeutic use
-
Pyrazoles / therapeutic use
-
Pyridones / therapeutic use
-
Risk Assessment
-
Rivaroxaban
-
Thiophenes / therapeutic use
-
Warfarin / therapeutic use
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / therapeutic use
Substances
-
Anticoagulants
-
Antithrombins
-
Benzimidazoles
-
Factor Xa Inhibitors
-
Morpholines
-
Pyrazoles
-
Pyridones
-
Thiophenes
-
beta-Alanine
-
apixaban
-
Warfarin
-
Rivaroxaban
-
Dabigatran
-
Aspirin